ALK inhibitors: What is the best way to treat patients with ALK+ non-small-cell lung cancer?

Clinical Lung Cancer

Volumn 15, Issue 5, 2014, Pages 313-319

  Toyokawa, Gouji ^a   Seto, Takashi ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

ALK inhibitors; Anaplastic lymphoma kinase; Crizotinib; Non small cell lung cancer; Resistance mechanisms

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CRIZOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANAPLASTIC LYMPHOMA KINASE GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; GENE ACTIVATION; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE K RAS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VASCULOTROPIN RECEPTOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84908224945     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.05.001     Document Type: Review

References (59)

1. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial Lancet Oncol 11 2010 121 128
2. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
3. K. Takeuchi, M. Soda, and Y. Togashi RET, ROS1 and ALK fusions in lung cancer Nat Med 18 2012 378 381
4. D. Lipson, M. Capelletti, and R. Yelensky Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat Med 18 2012 382 384
5. J. Mazieres, S. Peters, and B. Lepage Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J Clin Oncol 31 2013 1997 2003
6. A. Vaishnavi, M. Capelletti, and A.T. Le Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer Nat Med 19 2013 1469 1472
7. T.S. Mok Personalized medicine in lung cancer: what we need to know Nat Rev Clin Oncol 8 2011 661 668
8. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
9. H. Mano Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer Cancer Sci 99 2008 2349 2556
10. M. Soda, K. Isobe, and A. Inoue A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer Clin Cancer Res 18 2012 5682 5689
11. J.F. Gainor, A.M. Varghese, and S.H. Ou ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer Clin Cancer Res 19 2013 4273 4281
12. D.R. Camidge, S.A. Kono, and A. Flacco Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
13. T. Sasaki, S.J. Rodig, L.R. Chirieac, and P.A. Janne The biology and treatment of EML4-ALK non-small cell lung cancer Eur J Cancer 46 2010 1773 1780
14. J.M. Heuckmann, H. Balke-Want, and F. Malchers Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants Clin Cancer Res 18 2012 4682 4690
15. K. Takeuchi, Y.L. Choi, and Y. Togashi KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 2009 3143 3149
16. K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
17. E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
18. D.R. Camidge, Y.J. Bang, and E.L. Kwak Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
19. D.R. Camidge, and R.C. Doebele Treating ALK-positive lung cancer - early success and future challenges Nat Rev Clin Oncol 9 2012 268 277
20. T. Seto, K. Kiura, and M. Nishio CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Lancet Oncol 14 2013 590 598
21. Inoue A, Nishio M, Kiura K, et al. One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). Paper presented at the 15th World Conference on Lung Cancer; October 27-31 2013; Sydney, Australia: P3.11-034.
22. B. Solomon, K.D. Wilner, and A.T. Shaw Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer Clin Phamacol Ther 95 2013 15 23
23. A.T. Shaw, R. Mehra, and D.W. Kim Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC J Clin Oncol 31 suppl 2013 abstract 8010
24. J.G. Christensen, H.Y. Zou, and M.E. Arango Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol Cancer Ther 6 2007 3314 3322
25. U. McDermott, A.J. lafrate, and N.S. Gray Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res 68 2008 3389 3395
26. J.J. Cui, M. Tran-Dubé, and H. Shen Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J Med Chem 54 2011 6342 6363
27. T. Komiya, A. Thomas, and S. Khozin Response to crizotinib in ROS1-rearranged non-small-cell lung cancer J Clin Oncol 30 2012 3425 3426
28. R.H. Palmer, E. Vernersson, and C. Grabbe Anaplastic lymphoma kinase: signaling in development and disease Biochem J 420 2009 345 361
29. Kim DW, Ahn M-J, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Paper presented at the ESMO 2012 Conference; September 28-October 2, 2012; Vienna, Austria (abstract 2252).
30. Y.L. Choi, M. Soda, and Y. Yamashita EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N Engl J Med 363 2010 1734 1739
31. M.E. Gorre, M. Mohammed, and K. Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
32. W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
33. S. Zhang, F. Wang, and J. Keats Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen Chem Biol Drug Des 78 2011 999 1005
34. C. Gridelli, S. Peters, and A. Sgambato ALK inhibitors in the treatment of advanced NSCLC Cancer Treat Rev 40 2014 300 306
35. R.C. Doebele, A.B. Pilling, and D.L. Aisner Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
36. D. Maillet, I. Martel-Lafay, and D. Arpin Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement J Thorac Oncol 8 2013 e30 e31
37. H. Kaneda, I. Okamoto, and K. Nakagawa Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer J Thorac Oncol 8 2013 e32 e33
38. J.F. Gainor, S.H. Ou, and J. Logan The central nervous system as a sanctuary site in alk-positive non-small cell lung cancer J Thorac Oncol 8 2013 1570 1573
39. N. Peled, L. Zach, and O. Liran Effective crizotinib schedule for brain metastases in alk rearrangement metastatic non-small-cell lung cancer J Thorac Oncol 8 2013 e112 e113
40. R. Katayama, A.T. Shaw, and T.M. Khan Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 2012 120ra17
41. Y. Kobayashi, Y. Sakao, and S. Ito Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies J Thorac Oncol 8 2013 e75 e78
42. G. Toyokawa, M. Takenoyama, and S. Watanabe Dramatic response to crizotinib in an ALK-positive adenocarcinoma with disseminated intravascular coagulation J Thorac Oncol 8 2013 e96 e98
43. G. Toyokawa, T. Seto, and M. Takenoyama Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol 9 2014 e27 e28
44. H. Sakamoto, T. Tsukaguchi, and S. Hiroshima CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 2011 679 690
45. K. Kinoshita, K. Asoh, and N. Furuichi Design and synthesis of a highly selective, orally active and potent anaplastic kinase inhibitor Bioorg Med Chem 20 2012 1271 1280
46. T.H. Marsilje, W. Pei, and B. Chen Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) Inhibitor 5-Chloro-n2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J Med Chem 56 2013 5675 5690
47. R. Katayama, T.M. Khan, and C. Benes Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harbouring the fusion oncogene EML4-ALK Proc Natl Acad Sci U S A 108 2011 7535 7540
48. Z. Chen, E.A. Akbay, and O.R. Mikse Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance Clin Cancer Res 20 2014 1204 1211
49. D.R. Camidge, S.A. Kono, and X. Lu Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
50. J. Sang, J. Acquaviva, and J.C. Friedland Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer Cancer Discov 3 2013 430 443
51. +) or EGFR mutated advanced non-small cell lung cancer Ann Oncol 23 2012 ix152:abstract 4380
52. A.V. Galkin, J.S. Melnick, and S. Kim Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc Natl Aced Sci U S A 104 2007 270 275
53. R. Mehra, D.R. Camidge, and S. Sharma First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors J Clin Oncol 30 suppl 2012 abstract 3007
54. Seto T, Murakami H, Hirai F, et al. Phase I study of the ALK inhibitor LDK378 in Japanese patients with advanced, ALK-rearranged NSCLC and other tumors harboring genetic ALK alterations. Paper presented at the 15th World Conference on Lung Cancer; October 27-31 2013; Sydney, Australia: P1.11-007.
55. D.R. Camidge, L. Bazhenova, and R. Salgia First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results J Clin Oncol 31 suppl 2013 abstract 8031
56. S. Kuromitsu, M. Mori, and I. Shimada Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models Mol Cancer Ther 10 suppl 2011 abstract A227
57. Mori M, Kuromitsu S, Ueno Y, et al. ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; March 31-April 4, 2012; Chicago, IL (abstract 866).
58. C.M. Lovly, J.M. Heuckmann, and E. de Stanchina Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res 71 2011 4920 4931
59. J.M. Ostrem, U. Peters, and M.L. Sos K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Nature 503 2013 548 551